Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clevudine vs Lamivudine in Chronic Hepatitis B
NCT00362635Phase 3Completed
- Sponsor
- Bukwang Pharmaceutical
- Start
- Aug 2006
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of clevudine in Chronic Hepatitis B (CHB) (2 arms), sponsored by Bukwang Pharmaceutical. Primary endpoints: Incident rate of HBV DNA negativity (<300 copies/ml) at 48 weeks and Laboratory tests, Adverse Events, Physical examination at 48 weeks. Started Aug 2006; status: completed.
02
Drugs
clevudine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT00362635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00362635.